Literature DB >> 26160700

Hematopoietic Cell and Renal Transplantation in Plasma Cell Dyscrasia Patients.

Olga Baraldi1, Valeria Grandinetti, Gabriele Donati, Giorgia Comai, Giuseppe Battaglino, Vania Cuna, Irene Capelli, Elisa Sala, Gaetano La Manna.   

Abstract

Gammopathies, multiple myeloma, and amyloidosis are plasma dyscrasias characterized by clonal proliferation and immunoglobulin overproduction. Renal impairment is the most common and serious complication with an incidence of 20-30% patients at the diagnosis. Kidney transplant has not been considered feasible in the presence of plasma dyscrasias because the immunosuppressive therapy may increase the risk of neoplasia progression, and paraproteins may affect the graft. However, recent advances in clinical management of multiple myeloma and other gammopathies allow considering kidney transplant as a possible alternative to dialysis. Numerous evidence indicates the direct relationship between hematological remission and renal function restoring. The combination of kidney and hematopoietic cell transplant has been reported as a promising approach to reestablish end-organ function and effectively treat the underlying disease. This review describes current protocols used to perform kidney transplantation in patients with plasma dyscrasias.

Entities:  

Mesh:

Year:  2015        PMID: 26160700     DOI: 10.3727/096368915X688560

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  3 in total

1.  Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma.

Authors:  D Bhowmik; S Yadav; L Kumar; S Agarwal; S K Agarwal; S Gupta
Journal:  Indian J Nephrol       Date:  2017 Jul-Aug

2.  Risk of relapse of multiple myeloma following kidney transplantation.

Authors:  Sapna Shah; Maria Ibrahim; Michael Delaney; Steve Schey; Ceri Bygrave; Matthew Streetly; Reuben Benjamin
Journal:  Clin Kidney J       Date:  2019-01-25

Review 3.  Cerebral Small Vessel Disease.

Authors:  Qian Li; Yang Yang; Cesar Reis; Tao Tao; Wanwei Li; Xiaogang Li; John H Zhang
Journal:  Cell Transplant       Date:  2018-09-25       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.